Page last updated: 2024-08-24

fadrozole and Breast Cancer

fadrozole has been researched along with Breast Cancer in 80 studies

Research

Studies (80)

Timeframe	Studies, this research(%)	All Research%
pre-1990	3 (3.75)	18.7374
1990's	52 (65.00)	18.2507
2000's	16 (20.00)	29.6817
2010's	7 (8.75)	24.3611
2020's	2 (2.50)	2.80

Authors

Authors	Studies
Muftuoglu, Y; Mustata, G	1
Hartmann, RW; Hu, Q; Yin, L	2
Chen, JZ; Khan, MZI; Nazli, A; Uzair, M	1
Amaral, C; Fernandes, PA; Ferreira Almeida, C; João Ramos, M; Oliveira, A; Teixeira, N	1
Brixius-Anderko, S; Scott, EE	1
Lin, JB; Mast, N; Pikuleva, IA	1
Ali, SM; Demers, L; Evans, DB; Evans, M; Leitzel, K; Lipton, A; Vo, MN; Wilson, M	1
Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nagase, H; Noguchi, S	1
Ali, SM; Allard, JW; Carney, W; Chinchilli, VM; Demers, L; Engle, L; Harvey, HA; Leitzel, K; Lipton, A	1
Adachi, I; Ikeda, T; Ohashi, Y; Sasaki, Y; Suwa, T; Tabei, T; Takatsuka, Y; Toi, M; Tominaga, T	1
de Jong, PC; Dingemans, M; Heneweer, M; Muusse, M; Sanderson, JT; van den Berg, M	1
Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Milella, M; Mottolese, M; Nisticò, C; Papaldo, P; Ruggeri, EM; Terzoli, E	1
Ioannidis, JP; Mauri, D; Pavlidis, N; Polyzos, NP	1
Ali, SM; Brown-Shimer, S; Carney, W; Demers, L; Evans, DB; Hamer, P; Leitzel, K; Lipton, A; Pierce, K	1
Dutta, U; Pant, K	1
Tsukagoshi, S	1
Nakao, K; Tanaka, M; Yano, S	1
Chinchilli, VM; Demers, L; Grossberg, H; Harvey, H; Konrad, K; Leitzel, K; Lipton, A; Teramoto, Y; Volas, G	1
Coombes, RC; Dowsett, M; Moore, J; Powles, TJ; Rubens, R; Smith, IE; Smithers, D; Trunet, PF	1
Demers, LM	1
Bennett, P; Brünner, N; Dombernowsky, P; Herrstedt, J; Svenstrup, B; Wachmann, H	1
Manni, A	1
Abe, O; Abe, R; Asaishi, K; Enomoto, K; Kajiwara, T; Nomura, Y; Tominaga, T; Wada, T; Yoshida, M	1
Abe, O; Koyama, H; Nomura, Y; Oohashi, Y; Takashima, S; Wada, T	1
Abe, O; Abe, R; Aoyama, H; Asaishi, K; Enomoto, K; Kajiwara, T; Ohasi, Y; Tominaga, T; Yoshida, M	1
Abe, O; Ando, J; Enomoto, K; Fujiwara, K; Hayashi, K; Hisamatsu, K; Imoto, S; Nomura, Y; Tashiro, H; Tominaga, T	1
Ashworth, A; Dowsett, M; Gledhill, J; Macaulay, V; McKinna, JA; Nicholls, J; Ryde, C; Smith, IE	1
Demers, LM; Hanagan, J; Harvey, HA; Lipton, A; Mulagha, M; Santen, RJ	1
Kanno, H; Kim, T; Kitawaki, J; Noguchi, T; Okada, H; Yamamoto, T	1
Höffken, K	1
Bonomi, P; Buzdar, AU; Cooper, J; Favis, G; Keller, AM; Mulagha, M; Smith, R; Vogel, C	1
Demers, L; Grossberg, H; Leitzel, K; Lipton, A; Teramoto, Y; Volas, GH	1
Cooper, J; Henderson, IC; Lipton, A; Miller, AA; Mulagha, MT; Navari, R	1
Fujikura, T; Ideyama, Y; Kudoh, M; Mori, M; Nanya, T; Shikama, H; Susaki, Y	1
Buzdar, AU; Hortobagyi, GN; Plourde, PV	1
Falkson, CI; Falkson, HC	1
Bacchi, M; Beretta, K; Castiglione-Gertsch, M; Cavalli, F; Fey, M; Goldhirsch, A; Jungi, WF; Löhnert, T; Senn, HJ; Thürlimann, B	1
Izumisawa, Y; Kato, M; Kawashima, S; Koshimizu, I; Nakagane, T; Sakato, M; Sakita, K; Sato, M; Yaguchi, S; Yoshioka, K	1
Akiyama, H; Hisamatsu, K; Iwamori, S; Minami, K; Ota, K; Tanabe, K	1
Durgam, VR; Tekmal, RR	1
Arai, K; Imai, R; Ito, K; Kojima, K; Muro, H; Nakagami, K; Nakajima, N; Nishimura, K; Onogawa, S; Suzuki, M; Tohyama, K; Umeda, Y	1
Fukuda, K; Kim, YH; Kitano, H; Kokufu, I; Peng, YF; Yamada, K; Yamamoto, M; Yano, T	2
Norton, A; Smith, IE	1
Chinchilli, VM; Costa, LA; Demers, LM; Harvey, HA; Kopreski, MS; Lipton, A; Santen, RJ	1
Coombes, RC	1
Tominaga, T	1
Kanzaki, M; Kojima, K; Machida, H; Nakaya, Y; Ohba, M; Tobayama, S; Toda, H	1
Fukuda, M; Shimizu, S; Suda, T; Watanabe, H	1
Dowsett, M	2
Smith, IE	1
Fujii, T; Hanaoka, T; Ishida, K; Kawashima, K; Mihara, Y; Takahashi, T	1
Sonoo, H	1
Ando, T; Ide, M; Kobayashi, M; Kuwano, H; Mochida, Y; Ohno, Y; Sekihara, M; Tsuzuki, Y; Uchida, N; Yoshikawa, M	1
Kimura, M; Nomura, Y; Ohashi, Y; Takashima, S; Toge, T; Tominaga, T	1
Kurebayashi, J; Sonoo, H	1
Buzdar, A; Howell, A	1
Chino, Y; Ogata, M; Suzuki, Y; Tani, T; Ubukata, N; Yoshihara, K	1
Hirayama, K; Nakajima, Y; Nishiyama, S; Saitoh, K; Shimada, T; Shimizu, T; Terashima, H	1
Buzdar, AU	1
Borja, J; Pérez, N	1
Falkson, G; Falkson, HC; Raats, JI	2
Demers, LM; Garber, JE; Hanagan, J; Harvey, H; Henderson, IC; Lipton, A; Lynch, J; Mulagha, M; Navari, RM; Santen, RJ	1
Dowsett, M; Haynes, B; Jacobs, S; Jones, A; Lønning, PE; Powles, T	1
Santen, RJ	2
Coombes, RC; Davenport, J; Dowsett, M; Ford, HT; Gazet, JC; Hedley, A; Stein, RC	1
Demers, LM; Fitzsimmons, S; Hanagan, JR; Harvey, HA; Kochak, GM; Lipton, A; Mulagha, MT; Sanders, SI; Santen, RJ	1
Dowsett, M; Lønning, PE; Powles, TJ	1
Langecker, P; Rajfer, J; Santen, RJ; Santner, SJ; Sikka, S; Swerdloff, R	1
Coombes, RC; Dowsett, M; Mehta, A; Stein, RC	1
Klepp, R; Kvinnsland, S; Lønning, PE	1
Beretta, KR; Bhatnagar, AS; Cavalli, F; Chaudri, HA; Goldhirsch, A; Hoeffken, K; Kvinnsland, S; Trunet, P	1
Demers, LM; Harvey, HA; Lipton, A; Melby, JC; Santen, RJ; Wilson, TE	1
Adlercreutz, H; Demers, LM; Harvey, H; Lipton, A; Sanders, S; Santen, RJ; Santner, S	1
Miller, WR	1
Nicholls, PJ; Shaw, MA; Smith, HJ	1

Reviews

23 review(s) available for fadrozole and Breast Cancer

Article	Year
An overview on Estrogen receptors signaling and its ligands in breast cancer. European journal of medicinal chemistry, 2022, Nov-05, Volume: 241 Topics: Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Ligands; Male; Receptors, Estrogen	2022
Estrogen receptor-positive (ER Biochemical pharmacology, 2020, Volume: 177 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Fulvestrant; Gene Expression; Humans; Molecular Targeted Therapy; Tamoxifen	2020
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer, 2005, Oct-01, Volume: 104, Issue:7 Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Probability; Prognosis; Remission Induction; Risk Assessment; Survival Analysis; Triazoles	2005
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. Journal of the National Cancer Institute, 2006, Sep-20, Volume: 98, Issue:18 Topics: Adult; Aged; Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles	2006
Aromatase inhibitors: past, present and future in breast cancer therapy. Medical oncology (Northwood, London, England), 2008, Volume: 25, Issue:2 Topics: Aminoglutethimide; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Fadrozole; Female; Humans; Letrozole; Nitriles; Triazoles	2008
Clinical use of aromatase inhibitors in the treatment of breast cancers. Journal of cellular biochemistry. Supplement, 1993, Volume: 17G Topics: Aminoglutethimide; Animals; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Letrozole; Nitriles; Rats; Triazoles	1993
Experience with aromatase inhibitors in the treatment of advanced breast cancer. Cancer treatment reviews, 1993, Volume: 19 Suppl B Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Forecasting; Humans	1993
Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects. Breast cancer research and treatment, 1998, Volume: 49 Suppl 1 Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Fadrozole; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Triazoles	1998
Aromatase inhibitors and their use in the adjuvant setting. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1998, Volume: 152 Topics: Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Fadrozole; Female; Humans	1998
[Recent development of oral anti-cancer drugs for breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:3 Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Administration Schedule; Fadrozole; Female; Floxuridine; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Medroxyprogesterone Acetate; Survival Rate; Tamoxifen; Toremifene	1999
Drug and hormone interactions of aromatase inhibitors. Endocrine-related cancer, 1999, Volume: 6, Issue:2 Topics: Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Interactions; Enzyme Inhibitors; Estrogens; Fadrozole; Female; Humans; Letrozole; Male; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Sensitivity and Specificity; Tamoxifen; Triazoles	1999
Aromatase inhibitors: a dose-response effect? Endocrine-related cancer, 1999, Volume: 6, Issue:2 Topics: Aminoglutethimide; Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estrogens; Fadrozole; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles	1999
[Aromatase inhibitors for treatment of advanced breast cancers]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58 Suppl Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Fadrozole; Female; Humans; Letrozole; Nitriles; Treatment Outcome; Triazoles	2000
[Endocrine therapy for advanced or recurrent breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:7 Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Fadrozole; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Neoplasm Recurrence, Local; Tamoxifen; Toremifene	2001
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:9 Topics: Anastrozole; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Fadrozole; Female; Headache; Humans; Letrozole; Nausea; Nitriles; Treatment Outcome; Triazoles; Vomiting	2001
A summary of second-line randomized studies of aromatase inhibitors. The Journal of steroid biochemistry and molecular biology, 2001, Volume: 79, Issue:1-5 Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Enzyme Inhibitors; Estrogen Receptor Modulators; Fadrozole; Female; Humans; Letrozole; Megestrol Acetate; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles	2001
Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer. The Journal of international medical research, 1992, Volume: 20, Issue:4 Topics: Aminoglutethimide; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Imidazoles; Letrozole; Nitriles; Triazoles	1992
Clinical use of aromatase inhibitors in human breast carcinoma. The Journal of steroid biochemistry and molecular biology, 1991, Volume: 40, Issue:1-3 Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Fadrozole; Humans; Imidazoles; Nitriles	1991
Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. Journal of steroid biochemistry, 1990, Volume: 35, Issue:3-4 Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Fadrozole; Female; Humans; Imidazoles; Menopause; Nitriles	1990
Recent progress in development of aromatase inhibitors. The Journal of steroid biochemistry and molecular biology, 1990, Dec-20, Volume: 37, Issue:6 Topics: Aminoglutethimide; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Fadrozole; Humans; Imidazoles; Nitriles	1990
Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer. The Journal of steroid biochemistry and molecular biology, 1990, Dec-20, Volume: 37, Issue:6 Topics: Aminoglutethimide; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Estrogen Antagonists; Fadrozole; Humans; Imidazoles; Nitriles	1990
Aromatase inhibitors in the treatment of advanced breast cancer. Cancer treatment reviews, 1989, Volume: 16, Issue:2 Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Imidazoles; Neoplasms, Hormone-Dependent; Nitriles	1989
Aminoglutethimide and ketoconazole: historical perspectives and future prospects. Journal of steroid biochemistry, 1988, Volume: 31, Issue:1 Topics: Adrenal Gland Neoplasms; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Imidazoles; Ketoconazole; Male; Nitriles; Prostatic Neoplasms	1988

Trials

26 trial(s) available for fadrozole and Breast Cancer

Article	Year
Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy. Breast cancer research and treatment, 2010, Volume: 119, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Drug Resistance, Neoplasm; Endoglin; Enzyme-Linked Immunosorbent Assay; Fadrozole; Female; Humans; Kaplan-Meier Estimate; Megestrol Acetate; Middle Aged; Receptors, Cell Surface	2010
Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clinical chemistry, 2002, Volume: 48, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Fadrozole; Female; Humans; Megestrol Acetate; Middle Aged; Mucin-1; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Retrospective Studies	2002
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:1 Topics: Administration, Oral; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Estradiol; Estrone; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Safety; Survival Rate; Triazoles	2003
Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer, 2007, May-15, Volume: 109, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Fadrozole; Female; Humans; Megestrol Acetate; Middle Aged; Prognosis; Receptor, ErbB-2; Survival Rate; Tissue Inhibitor of Metalloproteinase-1	2007
[Introduction of a new aromatase inhibitor fadrozole hydrochloride hydsate]. Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:13 Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Fadrozole; Female; Humans; Mammary Neoplasms, Experimental; Rats	1995
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antigens; Breast Neoplasms; Chi-Square Distribution; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Fadrozole; Female; Gene Amplification; Humans; Megestrol; Megestrol Acetate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Regression Analysis; Survival Analysis; Tamoxifen; Treatment Outcome	1995
Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Estradiol; Estrogens; Estrone; Fadrozole; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Postmenopause	1994
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast cancer research and treatment, 1994, Volume: 30, Issue:1 Topics: Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Estrone; Fadrozole; Female; Humans; Letrozole; Middle Aged; Nitriles; Radioimmunoassay; Triazoles	1994
Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A. European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:9 Topics: Aged; Androgens; Breast Neoplasms; Dose-Response Relationship, Drug; Estrogens; Fadrozole; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Postmenopause; Sex Hormone-Binding Globulin; Time Factors	1994
[Phase II study of CGS16949A, a new aromatase inhibitor--a dose finding study]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:4 Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Estradiol; Fadrozole; Female; Humans; Middle Aged; Nausea; Postmenopause; Vomiting	1994
[Late phase II study of CGS16949A, a new aromatase inhibitor--a multicentral cooperative study (Western Japan Group)]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:4 Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Estradiol; Estrone; Fadrozole; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause	1994
[Clinical evaluation of CGS16949A in advanced or recurrent breast cancer--a multi-institutional late phase II clinical trial]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:4 Topics: Administration, Oral; Adult; Aged; Anorexia; Breast Neoplasms; Drug Administration Schedule; Fadrozole; Female; Humans; Middle Aged; Nausea; Neoplasm Recurrence, Local; Postmenopause	1994
[Phase I study of CGS16949A--a new aromatase inhibitor. Cooperative Study Group for CGS16949A]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:2 Topics: Administration, Oral; Adult; Aged; Androgens; Breast Neoplasms; Drug Administration Schedule; Estrogens; Fadrozole; Female; Humans; Menopause; Middle Aged; Neoplasms, Hormone-Dependent	1994
The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer. The Journal of steroid biochemistry and molecular biology, 1993, Volume: 44, Issue:4-6 Topics: Adrenocorticotropic Hormone; Aldosterone; Breast Neoplasms; Estradiol; Estrone; Fadrozole; Female; Humans; Hydrocortisone; Neoplasm Staging	1993
Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer, 1996, Jun-15, Volume: 77, Issue:12 Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Double-Blind Method; Fadrozole; Female; Humans; Megestrol; Menopause; Middle Aged; Prognosis; Prospective Studies; Survival Analysis	1996
Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer, 1996, Jul-15, Volume: 78, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Fadrozole; Female; Humans; Megestrol; Megestrol Acetate; Placebos; Prognosis; Receptor, ErbB-2; Remission Induction; Treatment Outcome	1996
Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. Cancer, 1996, Aug-15, Volume: 78, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Dose-Response Relationship, Drug; Estrogen Antagonists; Fadrozole; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Postmenopause; Prospective Studies	1996
A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Confidence Intervals; Disease-Free Survival; Enzyme Inhibitors; Fadrozole; Female; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Prognosis; Prospective Studies; Survival Rate; Tamoxifen	1996
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Enzyme Inhibitors; Fadrozole; Female; Humans; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Tamoxifen	1996
[Clinical trial of fadrozole hydrochloride for postmenopausal patients with recurrent breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:7 Topics: Aged; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Fadrozole; Female; Humans; Lung Neoplasms; Middle Aged; Postmenopause; Survival Analysis	1999
[Sequential changes in hormone levels in postmenopausal breast cancer patients under long-term treatment with an aromatase inhibitor. Kanagawa AI Study Group]. Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:14 Topics: Aged; Androgens; Androstenedione; Androsterone; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estradiol; Estrogens; Fadrozole; Female; Humans; Hydrocortisone; Middle Aged; Postmenopause; Testosterone	1999
[A combined effect of fadrozole and tamoxifen in postmenopausal patients with recurrent breast cancer: a preliminary report: Japanese Cooperative Study Group of Fadrozole and Tamoxifen]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:11 Topics: Aged; Aldosterone; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Fadrozole; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Tamoxifen	2000
Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer. The Journal of steroid biochemistry and molecular biology, 1992, Volume: 43, Issue:1-3 Topics: Administration, Oral; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Dose-Response Relationship, Drug; Fadrozole; Female; Humans; Imidazoles; Middle Aged; Nitriles; Survival Analysis	1992
A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Estrogen Antagonists; Fadrozole; Female; Humans; Imidazoles; Life Tables; Menopause; Middle Aged; Nitriles; Survival Analysis; Treatment Outcome	1992
Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clinical endocrinology, 1990, Volume: 32, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogens; Estrone; Fadrozole; Female; Gonadal Steroid Hormones; Humans; Imidazoles; Menopause; Middle Aged; Neoplasm Metastasis; Nitriles; Randomized Controlled Trials as Topic	1990
CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study. Annals of oncology : official journal of the European Society for Medical Oncology, 1990, Volume: 1, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Estradiol; Estrone; Fadrozole; Female; Humans; Hydrocortisone; Imidazoles; Middle Aged; Nitriles; Remission Induction	1990

Other Studies

31 other study(ies) available for fadrozole and Breast Cancer

Article	Year
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorganic & medicinal chemistry letters, 2010, May-15, Volume: 20, Issue:10 Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Computer Simulation; Drug Design; Female; Humans; Models, Chemical; Models, Molecular; Structure-Activity Relationship	2010
Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer. Journal of medicinal chemistry, 2012, Aug-23, Volume: 55, Issue:16 Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cytochrome P-450 CYP11B2; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Female; Humans; In Vitro Techniques; Liver; Quinolones; Solubility; Steroid 11-beta-Hydroxylase; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship	2012
Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks. Journal of medicinal chemistry, 2013, Jan-24, Volume: 56, Issue:2 Topics: Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cytochrome P-450 CYP11B2; Female; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Quinolones; Risk Factors; Spectrometry, Mass, Electrospray Ionization	2013
Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design. The Journal of biological chemistry, 2019, 01-11, Volume: 294, Issue:2 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Catalytic Domain; Crystallography, X-Ray; Drug Design; Fadrozole; Female; Humans; Hydrocortisone; Molecular Docking Simulation; Protein Conformation; Steroid 11-beta-Hydroxylase	2019
Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy. Molecular pharmacology, 2015, Volume: 88, Issue:3 Topics: Adjuvants, Pharmaceutic; Anastrozole; Anilides; Animals; Antifungal Agents; Antineoplastic Agents; Breast Neoplasms; Cholestanetriol 26-Monooxygenase; Dexmedetomidine; Enzyme Inhibitors; Fadrozole; Female; Hypnotics and Sedatives; Mice; Mice, Inbred C57BL; Nitriles; Protein Binding; Thiazoles; Tosyl Compounds; Triazoles	2015
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors. Oncology, 2010, Volume: 79, Issue:1-2 Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Nitriles; Phosphorylation; Predictive Value of Tests; Prognosis; Retrospective Studies; Serine; Tamoxifen; Triazoles	2010
Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model. Toxicological sciences : an official journal of the Society of Toxicology, 2005, Volume: 83, Issue:2 Topics: Aromatase; Aromatase Inhibitors; Benzhydryl Compounds; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Coculture Techniques; Dexamethasone; Diethylstilbestrol; Drug Synergism; Estradiol; Fadrozole; Female; Fibroblasts; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mammary Glands, Human; Phenols; Prostaglandin-Endoperoxide Synthases; Proteins; RNA, Messenger; Transcription, Genetic; Trefoil Factor-1; Tumor Suppressor Proteins	2005
Anti-tumour effect of aromatase inhibitor, CGS16949A, on human breast cancer cells. European journal of pharmacology, 1995, Apr-28, Volume: 289, Issue:2 Topics: Aromatase; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Fadrozole; Humans; Testosterone; Time Factors; Tumor Cells, Cultured	1995
Control of aromatase in breast cancer cells and its importance for tumor growth. The Journal of steroid biochemistry and molecular biology, 1993, Volume: 44, Issue:4-6 Topics: Aromatase; Breast Neoplasms; Bucladesine; Cell Division; Dose-Response Relationship, Drug; Epidermal Growth Factor; Fadrozole; Female; Humans; Testosterone; Transforming Growth Factor alpha; Tumor Cells, Cultured	1993
Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: a new system for aromatase inhibitor screening. The Journal of steroid biochemistry and molecular biology, 1993, Volume: 44, Issue:4-6 Topics: Aminoglutethimide; Androstenedione; Androstenols; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Fadrozole; Female; Humans; Kinetics; Tumor Cells, Cultured	1993
Inhibitory effect of a novel non-steroidal aromatase inhibitor, YM511 on the proliferation of MCF-7 human breast cancer cell. The Journal of steroid biochemistry and molecular biology, 1996, Volume: 58, Issue:2 Topics: Adenocarcinoma; Aromatase Inhibitors; Breast Neoplasms; Cell Division; DNA; Enzyme Inhibitors; Estradiol; Fadrozole; Fluorouracil; Humans; Luciferases; Plasmids; Receptors, Estrogen; Testosterone; Transcription, Genetic; Transfection; Triazoles; Tumor Cells, Cultured	1996
Aromatase inhibitors in metastatic breast cancer. Seminars in oncology, 1996, Volume: 23, Issue:4 Suppl 9 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles	1996
In vitro cytotoxicity of imidazolyl-1,3,5-triazine derivatives. Biological & pharmaceutical bulletin, 1997, Volume: 20, Issue:6 Topics: Altretamine; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Drug Screening Assays, Antitumor; Fadrozole; Humans; Leukemia P388; Mice; Structure-Activity Relationship; Triazines; Tumor Cells, Cultured	1997
[A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:10 Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Enzyme Inhibitors; Fadrozole; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Neoplasm Recurrence, Local; Pleural Neoplasms; Premenopause	1997
A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene. Cancer letters, 1997, Sep-16, Volume: 118, Issue:1 Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminoglutethimide; Analysis of Variance; Anastrozole; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Enzyme Inhibitors; Fadrozole; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Ovariectomy; Postmenopause; Triazoles; Tumor Cells, Cultured	1997
[Liver metastases from breast cancer 14 years after radical mastectomy; successful treatment with hepatic arterial infusion chemotherapy and systemic endocrine therapy--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Fadrozole; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Lymphatic Metastasis; Mastectomy, Radical; Medroxyprogesterone; Mitomycin; Time Factors	1997
[A case of osteolytic metastases from breast cancer effectively treated with pamidronate]. Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Fadrozole; Female; Humans; Mastectomy; Middle Aged; Pamidronate	1998
Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma. Cancer, 1999, Jan-01, Volume: 85, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antithrombin III; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol; Enzyme Inhibitors; Estrogen Antagonists; Fadrozole; Female; Fibrinogen; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Middle Aged; Postmenopause; Protein C; Protein S; Risk Factors; Triglycerides	1999
[A case of pleural and mediastinal lymph node metastases from breast cancer effectively treated with fadrozole hydrochloride in combination with cyclophosphamide]. Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Enzyme Inhibitors; Fadrozole; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Mediastinum; Middle Aged; Pleura; Pleural Effusion, Malignant	1999
[Efficacy of combined chemoendocrine therapy with doxifluridine, cyclophosphamide, and fadrozole hydrochloride hydrate in a case of stage T4N3M1 breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:5 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Fadrozole; Female; Floxuridine; Humans; Lymphatic Metastasis	2000
Malignant proliferating trichilemmal tumor in the skin over the breast: a case report. Breast cancer (Tokyo, Japan), 2000, Volume: 7, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclophosphamide; Diagnostic Errors; Doxorubicin; Fadrozole; Female; Fluorouracil; Hair Diseases; Hair Follicle; Humans; Lymphatic Metastasis; Mastectomy, Radical; Mitomycin; Neoplasm Recurrence, Local; Skin Neoplasms	2000
[Hepatic infusion of docetaxel using PEIT for a patient with stage IV breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:12 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Ethanol; Fadrozole; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Injections, Intralesional; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids	2001
[An elderly woman with breast cancer and multiple liver metastasis that responded well to combination therapy of fadrozole and tamoxifen]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:13 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Fadrozole; Female; Humans; Liver Neoplasms; Tamoxifen	2001
Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. The Journal of clinical endocrinology and metabolism, 1991, Volume: 73, Issue:1 Topics: 17-alpha-Hydroxyprogesterone; Adrenocorticotropic Hormone; Aldosterone; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrone; Fadrozole; Female; Humans; Hydrocortisone; Hydroxyprogesterones; Imidazoles; Kinetics; Menopause; Nitriles	1991
The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. British journal of cancer, 1991, Volume: 63, Issue:5 Topics: Aged; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Estrone; Fadrozole; Female; Humans; Imidazoles; Middle Aged; Nitriles	1991
Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. Cancer research, 1990, Mar-01, Volume: 50, Issue:5 Topics: Aldosterone; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Electrolytes; Estradiol; Fadrozole; Female; Humans; Imidazoles; Menopause; Nitriles; Receptors, Estrogen	1990
A phase I trial of CGS 16949A. A new aromatase inhibitor. Cancer, 1990, Mar-15, Volume: 65, Issue:6 Topics: Adult; Aged; Androgens; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Estrogens; Fadrozole; Female; Humans; Imidazoles; Lymphatic Metastasis; Menopause; Middle Aged; Nitriles	1990
Potency and specificity of CGS-16949A as an aromatase inhibitor. Endocrine research, 1990, Volume: 16, Issue:1 Topics: Animals; Aromatase; Breast Neoplasms; Enzyme Inhibitors; Fadrozole; Female; Humans; Imidazoles; Nitriles; Ovary; Placenta; Swine	1990
Plasma estrone and estrone sulphate in breast cancer patients treated with the aromatase inhibitor CGS 16949A. Acta oncologica (Stockholm, Sweden), 1990, Volume: 29, Issue:4 Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estrone; Fadrozole; Humans; Imidazoles; Male; Middle Aged; Nitriles; Time Factors	1990
The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. The Journal of clinical endocrinology and metabolism, 1990, Volume: 70, Issue:4 Topics: 18-Hydroxycorticosterone; Adrenal Cortex; Adrenocorticotropic Hormone; Aged; Aldosterone; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Chemical Phenomena; Chemistry; Cytochrome P-450 CYP11B2; Cytochrome P-450 Enzyme Inhibitors; Electrolytes; Fadrozole; Female; Humans; Hydrocortisone; Imidazoles; In Vitro Techniques; Mineralocorticoids; Mixed Function Oxygenases; Nitriles	1990
Inhibition of aromatase with CGS 16949A in postmenopausal women. The Journal of clinical endocrinology and metabolism, 1989, Volume: 68, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Androgens; Aromatase Inhibitors; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Tolerance; Estrogens; Fadrozole; Female; Humans; Hydrocortisone; Imidazoles; Menopause; Nitriles	1989